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Randomised Double-blind Placebo Controlled Trial of Topical Autologous
Platelet Lysate in Venous Ulcer Healing
M. C. Stacey∗, S. D. Mata, N. J. Trengove and C. A. Mather
University Department of Surgery, Fremantle Hospital, PO Box 480, Fremantle, WA 6160, Australia
Objectives: to assess the effect of topical autologous platelet lysate on the healing of chronic venous ulcers.
Design: a randomised placebo controlled double-blind trial.
Materials: all patients had blood taken for preparation of autologous platelet lysate.
Methods: patients with proven chronic venous ulceration were randomised to the trial. Autologous platelet lysate or
placebo buffer solution were applied twice per week for up to 9 months in combination with standardised compression
bandaging.
Results: a total of 86 patients (36 males and 50 females, median age 70 years) were entered into the study. The patient
and treatment groups were equivalent for ulcer size, ulcer duration and other characteristics. Cox regression analysis of
the time to ulcer healing did not show any difference in healing between platelet lysate and placebo application.
Conclusions: platelet lysate prepared and delivered by the method used in this study had no influence on the healing of
chronic venous ulceration.
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Introduction Growth factors contained in platelets represent an
important physiological mixture of factors that may
be involved in the healing process.7 In acute wounds,The healing of chronic venous ulcers remains a major
platelets are present in the blood clot in the wound,clinical problem, with the mainstay of treatment being
and release many growth promoting factors that arecompression therapy.1 Apart from some advances in
present in the alpha granules. These factors are thoughtdressing technology, there have been few significant
to initiate the healing process.8 It has been proposedadvances in the treatment of chronic venous ulceration.
that the topical application of the mixture of growthThere are no specific agents or dressings that have
factors from platelets, to the surface of non-healingbeen demonstrated to speed up the healing process in
wounds might initiate the healing process.7 The mix-these chronic wounds.2 One reason for this is the lack
ture of growth factors may be collected as a releasateof understanding as to why the healing is deficient in
(platelet-derived wound healing factor) or a lysate.these ulcers.
The effect of platelet-derived factors has been dem-Many factors are involved in the healing process,
onstrated in cell culture and in in vitro studies inand included in these are inflammatory cells and cells
animals.7 Several clinical studies have attempted toof the skin immune system.3 These cells produce and
indicate the role of platelet-derived factors in chronicrespond to many humoral factors which include dif-
wounds.8–12 Some of these studies have consideredferent growth inducing cytokines.4
patients with multiple aetiologies of ulcers, with mul-Significant growth promoting effects of cytokines
tiple additional procedures being performed on thehave been demonstrated in in vitro studies on different
patients, and without an adequate control group. Onlycell types in tissue culture,5 and in wound healing
a small number of patients with venous ulcers havemodels in vivo.6 However, none of these models of
been studied, and conclusions on the influence ofimpaired wound healing is an adequate comparison
platelet-derived factors in treating venous ulcers areto chronic venous ulceration in humans.
not possible.
The aim of this study was to undertake a double-
∗ Please address all correspondence to: M. C. Stacey, University
blind placebo-controlled trial of topical platelet lysateDepartment of Surgery, Fremantle Hospital, PO Box 480, Fremantle,
Western Australia 6160, Australia. in the healing of proven chronic venous ulceration
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Table 1. Characteristics of the two treatment groups (data shown Table 2. Results of treatment for the two groups.
as median and ranges except where indicated).
Placebo Platelet lysate
Placebo Platelet lysate
Patients randomised 44 42
Withdrawals 6 5Patients 44 42
M:F 21:23 15:27 Failed to heal at 9 months 3 1
Failure of treatment before 9 months 1 3Age (years) 70 (26–92) 72 (35–90)
Leg (L:R) 23:21 22:20 Healed 34 33
Area (cm2):
Median (range) 2.09 (0.15–47.8) 1.79 (0.23–50.76)
Mean (±s.d.) 4.79 (±8.24) 5.06 (±8.70) Table 3. Cox regression analysis using covariate list as defined
Duration of current ulcer 3.0 (0.75–360) 3.0 (1–244) below.
(months)
Duration of ulcer history 60 (1–588) 69 (1–708) Covariates  Co-efficient p value
(months)
Number of ulcer episodes 2.5 (1–20) 2.0 (1–10) Lysate or placebo −0.126 0.37
Longest time with unhealed 6.0 (1–360) 6.0 (1–244) Ulcer area −0.053 0.02
ulcer (months) Duration of current ulcer −0.027 0.10
Duration of ulcer history −0.001 0.11
Number ulcer episodes −0.038 0.21
Longest unhealed ulcer −0.006 0.41to determine whether this could speed up healing,
Leg 0.14 0.29compared to optimal conventional therapy. Sex 0.12 0.39
Patients who had a proven venous ulcer were ran-Methods
domised into one of two treatment groups. Ran-
domisation was by a sealed envelope system whichPatients taking part in this study all had proven venous
was opened after all entry criteria were fulfilled andulceration, with no other possible cause for the poor
the patient had given informed consent. All patientshealing in their leg ulcer. Investigations undertaken to
had their leg ulcers treated at the leg ulcer clinic atdetermine the cause of ulceration were ankle/brachial
Fremantle Hospital. They attended twice weekly forarterial Doppler pressure index, venous refilling time
application of either platelet lysate or placebo and foron photoplethysmography and a series of blood tests
replacement of dressings and bandages. The dressingthat included full blood picture, erythrocyte sedi-
used was a piece of plain unbleached gauze placedmentation rate, urea and electrolytes, liver function
over the surface of the ulcer, this was then soakedtests, blood sugar level, rheumatoid serology and auto-
with either the platelet lysate or the placebo. The gauzeantibody tests. Patients were considered to have ven-
was cut to the exact size of the ulcer and it had beenous disease if venous refilling time was less than 25 s
predetermined that this would deliver a volume of(established standard for our laboratory),13 and arterial
150 l of the solution per cm2 of ulcer. It had also beendisease if arterial Doppler ratio was less than 0.9. All
demonstrated that mitogenic activity of the plateletpatients attending the leg ulcer clinic at Fremantle
lysate did not alter after 24 h in contact with thisHospital, who fulfilled the entry criteria, were con-
dressing (data not shown). The dressing was thensidered for entry to this study.
covered with a Viscopaste bandage (Smith & Nephew)
from the base of the toes to just below the knee,
followed by two Comprilan bandages (Beiersdorf)
Fig. 2. Life table graph showing healing of ulcers over time forFig. 1. Results of mitogenic assay on human foreskin fibroblasts
using 1% foetal calf serum (FCS) plus phosphate buffered saline both the control group (placebo) and the treatment group (platelet
lysate).(PBS), 1% FCS plus platelet lysate, and 5% FCS.
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from the base of the toes to just below the knee. A This study was approved by the Ethics Committees
of Fremantle Hospital and the University of WesternTubi-grip stockingette (Seton) was placed over the
Australia. Informed consent was obtained from allbandages to keep them in position.
patients. The sample size for the study was calculatedAt weekly intervals patients had their ulcers photo-
to give an 80% chance of being able to demonstrategraphed, traced and the size assessed by planimetry.
a 10% difference in ulcer healing at a 5% level ofThis gave an indication of the progress of healing of
significance. The characteristics of each group werethe ulcer. Treatment was continued either until the
compared using Wilcoxon rank sum test for numericulcer had healed, or for a total of 9 months. Patients
data and Chi-squared test for grouped data. Analysiswere considered as withdrawals from the study if they
of time to healing of ulcers was performed by Coxcould not continue the treatment for reasons that were
regression analysis using patient characteristics andunrelated to healing of the ulcer. If treatment had to
the type of solution applied as covariates. Using thisbe ceased for any reason related to the healing of the
analysis, data from all patients were included in theulcer, the patient was considered to have failed the
analysis. Data on patients who withdrew were ana-treatment. These reasons included the failure of the
lysed up to the point of leaving the study.ulcer to show any response over a 3-month period or
a dramatic increase in the size of the ulcer, such that
a change in the method of treatment was necessary.
ResultsThe platelet lysate was prepared from 70 ml of blood
from each patient, collected into tubes with ethy-
A total of 86 patients were randomised into this study.lenediamine tetra acetic acid (EDTA). This was then
There were 42 patients in the platelet lysate group andcentrifuged at 500 rpm for 70 min and placelet rich
44 in the control group. The specific characteristics ofplasma aspirated. A platelet count was performed
the two groups are shown in Table 1. These char-using a Coulter counter. The platelets were separated
acteristics were similar for both groups. The two(centrifugated at 3000 rpm for 10 min at room tem-
groups were equivalent for age and sex distribution.perature), and were re-suspended in 4 ml of phosphate
The data on the ulcer size are provided for both thebuffered saline (PBS). Platelets were isolated (cent- median and the mean value, since the mean is often
rifuged at 3000 rpm for 10 min) and re-suspended in represented in similar studies; however, the median
2 ml PBS and sonnicated for 25 s in 5 s bursts. Platelet gives a closer assessment of the size of ulcers being
fragments were removed (centrifuged at 4000 rpm) treated.
and the supernatant was re-suspended in a volume of There was no bacterial growth in any of the cultures
PBS that would have given an original concentration of samples of platelet lysate solution prepared in this
of platelets of 2×109 platelets per ml. All platelet lysate study. All samples, in all patients, showed evidence
solutions were tested for sterility and 1 ml aliquots of of mitogenic activity and an example of this is shown
the platelet lysate were frozen at −20 °C until used. in Figure 1, where the platelet lysate had additional
Similar 1 ml aliquots of PBS were also prepared as the mitogenic activity compared to that with phosphate
placebo solution. buffered saline. In all samples the amount of DNA
The platelet lysate solutions were all tested in a measured on assay was >0.6 g/ml which is ap-
fibroblast mitogenic assay to assess their mitogenic proximately three times that seen with buffer solution.
potential. This assay used human foreskin fibroblasts The results of treatment in each patient group are
from a primary culture established in this department. summarised in Table 2. There was no major difference
The cells were seeded onto 12 well plates at a cell in outcome between the two groups. There was no
density of 2×104 cells per well. The culture media evidence of any adverse effects specifically related to
contained 1% foetal calf serum, and either platelet the application of the platelet lysate solution. The
lysate or an equivalent volume of PBS was added. Cell reasons for withdrawal from the study were de-
proliferation was assessed after 4 days using a DABA velopment of an allergy to the paste bandage (five
reaction to measure the amount of DNA present in patients), moving out of the city where the study was
each culture well. being conducted (two patients), admission to hospital
At the completion of the study, collected samples for other medical reasons (two patients), trauma on
of platelet lysate were analysed using radio immuno the leg from bandages (one patient) and refusal to
assays for platelet derived growth factor (PDGF) and continue in study for personal reasons (one patient).
epidermal growth factor (EGF) (Amersham). These The results of the Cox regression analysis are shown
assays were performed to obtain levels of these growth in Table 3, and the only factor that significantly in-
fluenced the time to total healing was ulcer size.factors in the solution that was applied to the wounds.
Eur J Vasc Endovasc Surg Vol 19, September 2000
Autologous Platelet Lysate in Venous Ulcer Healing 299
The use of topical platelet lysate had no significant chronic venous ulcers was quite small. In only one
influence on venous ulcer healing. This is shown reported study were all of the ulcers due to venous
graphically in Figure 2, where the two treatment disease; however, the patient numbers were small.9
groups are represented in a life table graph. It can be No benefit from the application of platelet releasate
seen that in the control and the treatment groups more was shown in that study. Only patients with venous
than 75% of patients had healed their ulcers at 3 ulceration and with no other cause for delayed healing
months, without any apparent differences in the heal- were entered into our study. All had optimal com-
ing of these two groups. pression therapy and no additional treatments for their
Concentrations of PDGF and EGF in prepared plate- venous disease. The measure of healing was time to
let lysate were measured in all of the prepared samples. total healing of the ulcerated limb. There was no
The concentration of PDGF in the platelet lysate was suggestion of any benefit from applying the topical
43.4±32.0 ng/ml (standard deviation) and the con- platelet lysate in the manner described.
centration of EGF was 5.81±2.62 ng/ml. One potential confounding factor in the design of
this study is the lack of data on deep vein reflux and
post-thrombotic changes. Duplex scanning was not
undertaken on patients in this study because it was
Discussion not available to the authors on a routine basis at the
start of the study. If there was an uneven distribution
The concept of applying growth factors to chronic of deep vein abnormalities between the two groups,
wounds certainly has some appeal and can be sup- despite the process of randomisation, this could theo-
ported by studies that have shown improved healing retically influence the outcome of the study. Whether
in wound models in animals. Platelets contain a the presence of deep vein disease, as demonstrated by
physiological balance of factors that do play a role in venography or duplex scanning, actually influences
initiating the healing process. In this study, however, the speed of healing in venous ulcers has not been
no improvement was found in the time to healing of clearly demonstrated, but has been considered to be
chronic venous ulcers with the topical application of a potential factor that delays the healing of venousautologous platelet lysate, even though the individual
ulcers. It has been shown previously that phle-patient solutions were each shown to stimulate the
bographic evidence of deep vein damage and post-mitogenic activity of foreskin fibroblasts. There were
thrombotic changes does not influence the rate ofalso no observed adverse effects of applying this top-
venous ulcer healing.15 In a recent study using duplexical platelet lysate to chronic human wounds.
scanning, the presence of reflux in the deep veins didThere are differences between this and other studies
not influence the rate of venous ulcer healing.16 It isin the method of preparation and application of the
possible that when good compression methods areplatelet lysate. The levels of growth factors and the
used, as was the case in both of these previouslymitogenic potential of platelet lysate determined in
reported studies, as well as this study, the influencethis study are comparable to those reported for platelet
of factors such as deep vein changes may not bereleasate.14 Other studies have used platelet releasate
significant, whereas when less than optimal com-and have applied the material daily. Daily application
pression is used these factors may have an influenceis, however, not practical if this is to be undertaken
on ulcer healing.17in combination with optimal compression therapy to
The failure of the platelet lysate to have an effectthe legs, since patients have great difficulty applying
on healing indicates that these growth factors maybandages with the required level of compression and
already be present in adequate amounts and thatsupervision of this on a daily basis is extremely dif-
addition of more of these growth factors is not capableficult. The demonstration that platelet lysate applied
of speeding up the healing process. Since this studywith gauze dressing remains available and active at
was completed, we have assayed fluid from non-24 h indicates its continued availability to the wound.
healing and healing chronic wounds and have foundPrevious studies have provided little information
that there is no difference in the levels of PDGF, EGF,on the influence of these platelet extracts on chronic
basic fibroblast growth factor (b-FGF) or transformingvenous ulcers since they have treated wounds with
growth factor  (TGF-) when the ulcers are healingdifferent aetiologies and, in addition, other procedures
compared to the non-healing phase.18such as arterial bypass surgery have also been per-
The failure of the platelet lysate to influence healingformed. The measures of healing in most of these
may be related to the level of cytokines in the lysate.studies were not complete healing of the ulcerated
limbs. The number of patients in these studies with Although we were able to demonstrate that platelet
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lysate does have mitogenic activity, the ability to assay solution was released from the dressing that was used
and that the mitogenic potential of the solution wasthe levels of growth factors in the platelet lysate was
unchanged. This indicates the continued availabilitynot available to us at the outset of this study and
of the active factors in the lysate. In all studies thatlevels of PDGF and EGF were performed only at
use topical application of active agents it is difficultthe end of the study. PDGF and EGF are present in
to be certain that the agents are being incorporatedconcentrations approximately 1000 times lower than
into the wound itself. How this can be accuratelythose that have been demonstrated to have an effect
assessed is difficult to determine and has not beenon the healing process in wound models in animals.19,20
shown in any previous studies. However, it will be anIn addition, PDGF and EGF levels are considerably
important consideration for future studies in chroniclower than levels that have been used to influence the
wound healing. It is certainly possible that topicalhealing process in humans.21–23 It has, however, been
material may not influence the wound due to it beingargued that the combination of growth factors that is
bound to inhibitors, degraded by proteases or simplypresent in platelets may be more important than the
mechanically removed from the wound by exudate.concentration of individual factors. Clearly it would
This study indicates that platelet lysate preparedseem that there are insufficient quantities of these
and applied in the manner described has no benefitgrowth factors in platelet lysate solutions to have an
in the healing of chronic venous ulcers. In addition, itinfluence on chronic human wounds. The levels of
would appear from data on cytokine levels in plateletPDGF and EGF that were found in this study are
lysate and releasate, as well as data on cytokine levelssimilar to those that have been reported in platelet
in chronic wound fluid, that there can be little jus-releasate.14
tification for the use of these solutions in the treatmentAnother theoretical cause of the failure of the platelet
of chronic venous ulcers.lysate to have an effect on healing is the finding, since
this study was initiated, that high levels of proteinases
have been identified in chronic wound fluid.24 The
levels of some matrix metalloproteinases are 20–200 Acknowledgements
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